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The present study was carried out to determine whether this interaction occurs in man.
Materials and Methods
Five hypertensive patients on long-term medication with clonidine and a diuretic were asked to join the study. In each patient the same daily dose of clonidine and diuretic was maintained throughout the study, which was divided into three parts. The first was a period of baseline observation to ensure that control was adequate and consistent. The blood pressure, lying and standing, was measured with a sphygmomanometer on at least three occasions over at least three weeks. Several recordings were made at each visit, and the visits were kept as nearly as possible to the same time, most being made at the patient's home after work. Periods 2 and 3 each comprised two weeks during which the patient took either desipramine 75 mg/day or the same number of matched placebo tablets. The patients were allocated at random to start with either placebo or desipramine and the study was carried out under double-blind conditions. During periods 2 and 3 the patients were seen at least twice a week.
Only one patient (case 3) did not keep to the agreed protocol. His blood pressure rose considerably 24 hours after beginning with the active drug. This was associated with headache and profuse sweating. A reduction in the desipramine dose resultedin a lessening of symptoms, but the blood pressure remained high so the study was terminated.
Average blood pressure for each patient was calculated from the whole run-in period and from the second week of each treatment period except in case 3, where the comparative periods were week 1 of each treatment. Within-patient observations were compared by the unpaired Student's t test, and group observations by the paired t test.
Results
Four of the five patients showed a significant (P < 001) rise in blood pressure in at least one position on desipramine, while * Significantly greater than in placebo period (P < 0-01). t Significantly greater than in placebo period (P < 0 05).
the fifth showed a modest increase in his postural blood pressure fall. The group mean blood pressure rose in the desipramine period by an average of 21-9/15-3 mm Hg lying (P < 001) and 12-0/11*5 mm Hg standing (P < 0 05). The group mean blood pressures, lying and standing, are shown in table II for the three observation periods. The range of pretreatment values are included for comparison. The difference between the group mean blood pressure in baseline and placebo periods was not significant. The response of two patients to the introduction of desipramine is shown in figs. 1 and 2 . The blood pressure rise in the second week oftreatment shown in case 1 ( fig. 1 ) was the response most frequently observed. The early and more dranmatic rise of blood pressure shown in case 3 ( fig. 2 ) was similar to the hypertensive reactions induced by sudden clonidine withdrawal. 
Discussion
The introduction of desipramine in a double-blind trial caused a rise in arterial pressure in four out of five hypertensive patients on treatment with clonidine. The effect was more prominent in the supine position than in the erect. The increase in blood pressure when desipramine is added to a clonidine regimen is of less rapid onset than that reported with the interaction between bethanidine and tricyclic antidepressants. A rise in blood pressure within 24 hours of starting desipramine was seen in only one patient, and this was the only instance in which the blood pressure rose to the pretreatment level. In the three other patients the change, though less, resulted in unacceptable arterial pressure levels.
The mechanism of the hypotensive action of clonidine has not been fully established. There is evidence that it causes a reduction in central sympathetic outflow (Schmitt et al., 1968) , but Zaimis and Hanington (1969) showed that a peripheral mechanism may be involved. Peripheral adrenergic neurone blockade has been demonstrated at relatively low concentrations of clonidine (Werner et al., 1972) although there is no evidence that this drug is concentrated in adrenergic neurones, as are bethanidine and guanethidine. Desipramine may impair the hypotensive action of clonidine by an action on neuronal uptake, but the tricyclic compounds have other pharmacological actions, such as alpha-adrenoreceptor blockade, which could be relevant.
The clinical implications of this finding are evident. Clonidine now joins the list of hypotensive drugs-bethanidine, guanethidine, and debrisoquine (Mitchell et al., 1970 )-which cannot be used with impunity in conjunction with tricyclic antidepressant therapy. Only methyldopa has been shown by these workers to exert its full hypotensive effect in the presence of the tricyclic compounds.
Any patient whose blood pressure is controlled with clonidine and who requires therapy for concomitant depression should be carefully observed if tricyclic drugs are used.
